Eton Pharmaceuticals Inc (ETON)vsHaleon plc (HLN)
ETON
Eton Pharmaceuticals Inc
$27.40
-4.46%
HEALTHCARE · Cap: $889.70M
HLN
Haleon plc
$9.12
+1.79%
HEALTHCARE · Cap: $39.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 12588% more annual revenue ($11.03B vs $86.93M). HLN leads profitability with a 15.1% profit margin vs -1.7%. HLN earns a higher WallStSmart Score of 63/100 (C+).
ETON
Avoid29
out of 100
Grade: F
HLN
Buy63
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 40.4% year-over-year
Earnings expanding 92.0% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Trading at 24.5x book value
ROE of -4.8% — below average capital efficiency
Earnings declined 12.6%
Expensive relative to growth rate
0.6% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Revenue Growth. Revenue growth of 40.4% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, P/E Ratio, Price/Book. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : ETON
The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
ETON profiles as a hypergrowth stock while HLN is a value play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.89 — expect wider price swings.
ETON is growing revenue faster at 40.4% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 29/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global consumer health company formed from a spin-off of GlaxoSmithKline, focusing on delivering innovative health solutions across a diverse portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. By concentrating on key segments such as oral care, pain relief, and dietary supplements, Haleon effectively addresses the dynamic needs of consumers while capitalizing on strong brand equity. The company's dedication to sustainability and relentless innovation, combined with strategic investments in product development, positions it advantageously for sustained long-term growth, thereby enhancing health outcomes and maximizing shareholder value.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?